Atlantic International Stock (NASDAQ:ATLN)

Based in Billerica, Massachusetts, and established in 2013, Atlantic International Corp. (which operated as SeqLL Inc. until its name change in June 2024) underwent a significant corporate change on June 18, 2024, when it was acquired by Lyneer Investments, LLC, via a reverse merger. The company operates within the life sciences sector, providing specialized instrumentation and research services. Its primary focus is on generating innovative scientific assets and proprietary intellectual property across various "omics" disciplines. Central to its offerings is the True Single Molecule Sequencing (tSMS) platform. This advanced technology provides a unique single-molecule approach to DNA and RNA sequencing by directly detecting nucleic acids. It empowers researchers to analyze billions of individual molecules within a single experiment, ensuring the generation of highly accurate and reproducible data. Atlantic International's sophisticated solutions cater to diverse applications, including biomarker discovery and the development of diagnostic assays. Its clientele spans academic institutions (such as universities), governmental research centers, and leading companies in the biotechnology and pharmaceutical industries. The company also fosters key collaborations, including an R&D agreement with the U.S. Department of Justice's Federal Bureau of Investigation to assess the forensic potential of direct RNA sequencing using its tSMS platform, and a partnership with the Weizmann Institute of Science to advance and implement cutting-edge single-molecule technologies.